VTREND·Beyond the headlines
한국어

Alteogen’s 5,219억-Won Contract — What the Two Characters “Up to” Do

Alteogen’s 5,219억-won contract
Alteogen’s 5,219억-won contract

Alteogen disclosed on August 5 that it had entered into a licensing agreement with a global pharmaceutical company worth up to 3억 6,500만 dollars.

That is approximately 5,219억 won in Korean currency.

But that does not mean this money is entering the company now.

3-line summary
1. Alteogen’s 5,219억-won contract is not money it receives all at once.
2. The upfront payment will arrive within 30 days, while the rest will be paid in installments at each stage.
3. What matters is not the total contract value, but the upfront payment.

The Number With “Up to” Attached

In articles about biotech technology exports, “up to” appears almost without exception.

Looking at the company’s disclosure verbatim, it says, “up to 3억 6,500만 dollars, including upfront payment and development, regulatory approval, and commercialization milestones.” Put simply, some money is fixed the moment the contract is signed, while other money will be paid only if things proceed successfully at each future stage. Added together, those amounts equal 5,219억 won.

The latter is conditional. If development stops midway, the money for the next stage does not arrive.

There Are Three Paths for the Money to Arrive

In agreements to sell technology, money generally comes in through three channels. Distinguishing among them makes the figures in such articles much easier to read.

An upfront payment is money fixed at the time of the contract. It has no conditions. Alteogen said it expects to receive this upfront payment within 30 days from August 5, when the contract takes effect. However, the amount has not been confirmed in this announcement.

A milestone is money received each time a promised point is passed. Examples include entering the next stage of a clinical trial, receiving regulatory approval, and making the first sale. If that point is not reached, the money simply does not exist.

Royalties are received as a certain percentage of sales after the product is actually sold. Under this agreement as well, they are to be paid separately on net sales after the first sale.

There is one more point to note here. Royalties are not included in the 5,219억 won above. It is called a total amount, but in fact it is not the total amount.

Why Not Pay It All at Once?

Most new-drug development stops somewhere along the way. From the buyer’s perspective, paying the entire price in advance for a technology whose viability remains unknown is a risky choice.

It is not bad for the seller either. If money comes in at each stage, the seller continues to have a stake in development proceeding even after handing over the contract.

Not paying and receiving everything at once is a way for both sides to share risk. This is where much of the reason technology-export agreements appear particularly complex comes from.

What This Company Sells Is Not a Drug

What Alteogen sold is an enzyme called ALT-B4.

It is a substance that converts intravenously administered drugs into subcutaneous injections. The principle is as follows: beneath our skin, a component called hyaluronan is arranged like a mesh, preventing drugs from spreading easily. This enzyme temporarily loosens that mesh so that the drug can be absorbed quickly.

For patients, what changes is time. Drugs that once had to be administered by IV for tens of minutes to several hours while sitting in a hospital can instead be completed with a single injection.

Because it sells not the drug itself but the method of delivering the drug into the body, it can develop the technology once and sell it repeatedly to multiple pharmaceutical companies. This is called platform technology. The reason Alteogen was able to sign three agreements this year is also that the product it sells is the same.

12조 Won and 655억 Won

This is where it is easy to become confused.

According to a PharmEdaily report, Alteogen’s cumulative technology-export amount surpassed 12조 won with this agreement. The three agreements signed this year alone total 12억 2,900만 dollars, or approximately 1조 8,000억 won.

However, according to an FnGuide estimate reported by The Korea Economic Daily, the company’s projected second-quarter revenue is 655억 won.

The gap between these figures does not mean there is a problem with the company; it is because the two figures count different things. The 12조 won is the upper limit if all future conditions are met, while 655억 won is revenue actually recognized in this quarter.

The total contract value is the maximum possible future amount, while revenue is the result to date. The two figures should not be placed side by side and compared.

What Moves Royalties Is Not the Contract

How royalties, the final stage in this structure, actually grow is shown by another figure released at the same time.

Second-quarter sales of “Keytruda Qlex,” the subcutaneous cancer-drug formulation of U.S. Merck (MSD) using ALT-B4, were tallied at 4억 6,300만 dollars. This was more than triple the 1억 2,800만 dollars recorded in the first quarter. This formulation’s share of total Keytruda sales also rose from 1.6% in the first quarter to 5.5% in the second quarter.

Royalties increase not on the day the contract is signed, but when this figure grows. The contract opens the door; the money comes in when the product sells behind that door.

Three Categories That Divide the Total Technology-Export Value

There are three things to check when reading a technology-export disclosure.

Check whether the upfront payment amount is stated. If only the total amount is provided and there is no upfront payment, it means the article contains no clue as to the likelihood that figure will be realized.

Check which stages the milestones are tied to. Milestones concentrated in development and approval stages differ in nature from those concentrated in sales stages.

Check whether royalties are included in the total amount or listed separately. They are generally separate, and over the long term, they could be larger.

Conclusion

“Up to ○○억 won” is not the size of the contract; it is the size of the contract if everything goes as well as possible.

In technology-export articles, there is only one word that refers to money actually fixed: upfront payment.

All the remaining figures concern things that will happen in the future.

References